Catalent Comprehensive Income 2012-2024 | CTLT

Catalent comprehensive income for the quarter ending September 30, 2024 was $-0.350B, a 9.79% decline year-over-year.

  • Catalent comprehensive income for 2024 was $-0.404B, a 14.12% increase from 2023.
  • Catalent comprehensive income for 2023 was $-0.354B, a 10.15% decline from 2022.
  • Catalent comprehensive income for 2022 was $-0.394B, a 24.29% increase from 2021.

Catalent Comprehensive Income 2012-2024 | CTLT

  • Catalent comprehensive income for 2024 was $-0.404B, a 14.12% increase from 2023.
  • Catalent comprehensive income for 2023 was $-0.354B, a 10.15% decline from 2022.
  • Catalent comprehensive income for 2022 was $-0.394B, a 24.29% increase from 2021.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.7B
Takeda Pharmaceutical (TAK)$42.4B
Sandoz Group AG (SDZNY)$19.3B
Merck (MKKGY)$18.8B
Astellas Pharma (ALPMY)$18.3B
United Therapeutics (UTHR)$16.4B
Summit Therapeutics (SMMT)$13.6B
Neurocrine Biosciences (NBIX)$12.7B
Shionogi (SGIOY)$11.8B
Jazz Pharmaceuticals (JAZZ)$7.6B
Madrigal Pharmaceuticals (MDGL)$7.2B
Orion OYJ (ORINY)$6.7B
Corcept Therapeutics (CORT)$5.9B
Ionis Pharmaceuticals (IONS)$5.4B
Crinetics Pharmaceuticals (CRNX)$5.3B
PTC Therapeutics (PTCT)$3.3B
Dyne Therapeutics (DYN)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
Soleno Therapeutics (SLNO)$2.4B
Arrowhead Pharmaceuticals (ARWR)$2.3B
Centessa Pharmaceuticals (CNTA)$2.1B
Evotec AG (EVO)$1.9B
NewAmsterdam Pharma (NAMS)$1.9B
Xencor (XNCR)$1.7B
Recursion Pharmaceuticals (RXRX)$1.6B
Harrow (HROW)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Cassava Sciences (SAVA)$1.5B
Indivior (INDV)$1.5B